-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下:我們將12個月目標價上調59美元至289美元,此舉綜合考慮了相對估值和現金流折現模型(DCF)分析。相對估值方面,我們對2027年預計EBITDA採用8.2倍的企業價值倍數,高於同業水準。我們認為,如果投資報酬率高於同業(約高出17%),則該公司應享有溢價估值。基於此,我們得出每股價值275美元。同時,我們的DCF模型假設未來10年自由現金流年增率為4.2%,之後為2.5%,得出每股價值303美元。我們將2026年每股收益預期上調14.86美元至27.85美元,並將2027年每股收益預期上調6.42美元至19.65美元。由於波斯灣原油產量受限,布蘭特原油和WTI原油之間的價差(通常為每桶4美元,目前已達每桶8美元)預計在第二季度大幅提升,我們認為這種情況在未來幾季也可能持續。 VLO在3月份最大限度地提高了航空燃油產量,考慮到市場供應短缺,我們認為這是合理的。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.